Global Mantle Cell Lymphoma Therapeutics Market 2019-2023

The global mantle cell lymphoma therapeutics market size will grow by USD 1.35 billion during 2019-2023. This market report provides a detailed analysis of the market by product (combination therapy and monotherapy) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on many market vendors, including Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.

Some of the key findings from our mantle cell lymphoma therapeutics market forecast report are summarized below

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global Mantle Cell Lymphoma Therapeutics Industry Overview

Until the last decade, there were no approved therapeutics to treat mantle cell lymphoma because it is a rare disease. The significant unmet need for the treatment of the condition gave immense growth opportunities to the vendors of the global mantle cell lymphoma market. The vendors have been focusing on the development of reliable therapeutics to treat various blood carcinomas, including mantle cell lymphoma. As a result, several therapeutics were approved in the last few years, increasing the sales of vendors. Therefore, recent approvals of drugs will significantly drive the mantle cell lymphoma therapeutics market growth at a CAGR of over 7% during the forecast period.

The strong prevalence of various types of blood cancer has increased the need for the development of advanced therapies such as kinase inhibitors and gene therapies. Therefore, vendors are increasingly collaborating and testing therapeutics to treat types of blood cancer. The success of efficacy of certain therapeutics on various types of blood cancer has increased the scope of improvement of therapeutics to treat mantle cell lymphoma. For instance, Merck, in collaboration with Icahn School of Medicine at Mount Sinai, is testing pembrolizumab at Phase I/II stage of development for the treatment of mantle cell lymphoma. These factors indicate that the launch of various novel therapies has increased. Therefore, the advent of novel therapies is one of the key mantle cell lymphoma therapeutics market trends. The trend will contribute to market growth during the forecast period.

Top Mantle Cell Lymphoma Therapeutics Companies Covered in this Market Research Report

The global mantle cell lymphoma therapeutics market is concentrated. To help clients improve their market positions, this report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. This mantle cell lymphoma therapeutics market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.

The report offers a detailed analysis of several leading mantle cell lymphoma therapeutics manufacturers, including:

• Allergan Plc
• AstraZeneca Plc
• Celgene Corp.
• Johnson & Johnson Services Inc.
• Takeda Pharmaceutical Co. Ltd.

Mantle Cell Lymphoma Therapeutics Market Segmentation Based on Product

• Combination therapy
• Monotherapy

The combination therapy segment held the largest market share in 2018. It will account for the highest global mantle cell lymphoma therapeutics market share over the forecast period. Advantages of combination therapy over monotherapy, reduced drug resistance, and rising development and commercialization of combination therapies are expected to promote the growth of the market segment in the forthcoming years. This report provides an accurate prediction of the contribution of all the segments to the growth of the mantle cell lymphoma therapeutics market size.

Mantle Cell Lymphoma Therapeutics Market Segmentation Based on Geographic Region

• Asia
• Europe
• North America
• ROW

With a complete study of the growth opportunities for the companies, it has been identified that North America will account for the highest share of the mantle cell lymphoma therapeutics market throughout the forecast period. Factors such as the high sales of approved drugs for the treatment of mantle cell lymphoma and increasing prevalence of various hematologic cancer types are contributing to the mantle cell lymphoma therapeutics market growth in this region.

Key Highlights of the Global Mantle Cell Lymphoma Therapeutics Market for the Forecast Years 2019-2023:

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the mantle cell lymphoma therapeutics market during the next five years
• precise estimation of the global mantle cell lymphoma therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the mantle cell lymphoma therapeutics industry across Asia, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details of factors that will challenge the growth of mantle cell lymphoma therapeutics companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch